News

January 28, 2025

ENA Respiratory Publishes Review of Development of Novel Intranasal Antiviral Host Defense Immune Enhancer INNA-051 in Antiviral Research

January 22, 2025

ENA Respiratory Successfully Completes Phase Ib Dosing of Antiviral Host Defense Immune Enhancer INNA-051 Dry Powder Formulation in Older Adults and Advances Study in Young Adults

January 13, 2025

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America

December 23, 2024

CUREator + deploys $18.5 million to eight local biomedtech startups in its first funding round

December 19, 2024

Certa Therapeutics Expands GPR68 Platform through Acquisition of OccuRx

December 11, 2024

CatalYm Highlights Visugromab’s Potential to Treat Cachexia in Cancer Patients at International SCWD Conference

December 6, 2024

Major Australian breakthrough could revolutionise hypertension treatment

November 21, 2024

Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers

November 1, 2024

PolyActiva Showcases Promising Clinical Data Highlighting its Polymer Technology’s Potential to Transform Glaucoma Care

October 28, 2024

Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy

October 18, 2024

Phase III trial results of novel triple combination pill for hypertension published in The Lancet

October 14, 2024

CUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators

September 16, 2024

Certa Therapeutics Announces International Non-Proprietary Name for its First-in-class GPR68 Inhibitor Asengeprast (FT011)

September 11, 2024

Brandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.

September 6, 2024

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

September 5, 2024

NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND

August 27, 2024

ENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051

July 16, 2024

CatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab

July 8, 2024

Myricx Bio Announces £90m ($114m) Series A Financing to Advance its Novel NMTi-ADC Therapeutics into Clinical Development

May 22, 2024

Up to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+

May 21, 2024

Pheon Therapeutics announces $120m Series B financing to fund development of its differentiated ADC pipeline

May 13, 2024

Respirion offers hope for people living with cystic fibrosis

May 7, 2024

Funding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential

April 29, 2024

ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator

April 18, 2024

Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic

April 2, 2024

Azura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases

March 1, 2024

$3 million in Funding to Support Early-Stage Biomedtech Projects Focused on Minimising Antimicrobial Resistance Thanks to the CSIRO

February 15, 2024

Brandon BioCatalyst, in partnership with ANDHealth, selected by Federal Government to deliver $50m Dementia and Cognitive Decline Incubator

January 23, 2024

Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy

December 6, 2023

CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023

November 27, 2023

Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies

November 26, 2023

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

November 16, 2023

Certa Therapeutics presents positive data from a Phase 2 clinical study highlighting the potential benefit of FT011 as a novel treatment for scleroderma

November 15, 2023

Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors

November 2, 2023

PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery,biodegradable ocular implant in glaucoma patients.

October 19, 2023

Myricx Bio Wins Best Poster at World ADC

October 9, 2023

Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease

September 27, 2023

Pathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer

September 27, 2023

Recruitment completes for second Phase III hypertension trial investigating GMRx2 (George Medicines)

September 11, 2023

New Data From an Influenza Challenge Study Further Support the Prophylactic Potential of INNA-051 to Accelerate Viral Clearance

September 5, 2023

Glyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer

August 23, 2023

VAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH

August 15, 2023

CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups

August 3, 2023

Cicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst

July 18, 2023

State Government Backs OncoRes Medical with Funding to Manufacture Digital Cancer ImagingDevice in WA

June 6, 2023

Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer

June 6, 2023

Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine

June 2, 2023

Glyscend Therapeutics Announces Positive Topline Phase 2a Clinical Results and Progress with GLY-200, a First-in-Class Treatment for Type 2 Diabetes and Obesity

May 24, 2023

Nineteen groundbreaking biotech projects selected for national incubator

May 22, 2023

EBR Systems meets endpoints early in pivotal SOLVE-CRT trial: paves way for FDA approval application and commercialisation

May 3, 2023

Healthcare Veteran, Zach Henderson to lead Global Kinetics as CEO

March 21, 2023

Brandon BioCatalyst, in partnership with ANDHealth, selected by the Federal Government to deliver $50m BioMedTech Incubator Program

March 10, 2023

Aravax initiates Phase 2 peanut allergy clinical trials in Australia

March 9, 2023

Tech entrepreneur amongst stellar cohort in latest Women in Leadership Development (WILD) Program, which is expanding with new Federal investment

February 14, 2023

Nasal Spray Significantly Accelerates Respiratory Virus Clearance in Phase 2a Clinical Study

February 10, 2023

Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)

February 6, 2023

Ground-breaking results in Phase 2 scleroderma study by Certa Therapeutics demonstrates improvement in more than 60% of patients

January 19, 2023

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access

January 10, 2023

ENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051

December 20, 2022

Billionaires Andrew and Nicola Forrest take aim at peanut allergy

December 20, 2022

Aravax commences Phase 2 development for peanut allergy therapy with $20m commitment to Series B round from Brandon Capital and Tenmile

December 6, 2022

Entact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement

December 6, 2022

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

November 22, 2022

CatalYm Closes EUR 50 Million Series C Financing to Expand and Accelerate Phase 2 Clinical Development of Visugromab in Patients with Solid Tumors

November 17, 2022

Azura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction

November 11, 2022

QUE Oncology’s non-hormonal therapy reduces hot flushes and night sweats in women with breast cancer, published in The Lancet

November 9, 2022

Brandon Capital Invests in Neuroscience Company NRG Therapeutics

November 9, 2022

First Aussies to get needle-free COVID-19 vaccine patch

November 9, 2022

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

November 4, 2022

Certa Therapeutics’ investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

November 4, 2022

Pathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022

November 2, 2022

First in-human use of OncoRes Medical’s cancer imaging technology successful

October 20, 2022

Azura Ophthalmics Expands Broad Intellectual Property Portfolio to 12 U.S. and European Patents

October 12, 2022

Opinion: Taking the leap: transitioning from academia to industry – by Christina Kulis

September 28, 2022

Azura Ophthalmics Provides Update on AZR-MD-001 Phase 2 Clinical Program Targeting Meibomian Gland Dysfunction

September 28, 2022

Brandon Capital co-Leads USD68M Series A Financing of London-Based ADC Company Pheon Therapeutics

September 21, 2022

Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)

September 21, 2022

Glyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment

September 15, 2022

Medisanté and George Medicines collaborate to bring Internet of Things (IoT) data collection to decentralised Phase III trial of single-pill triple combination candidate to treat hypertension

September 8, 2022

George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial

September 5, 2022

$16m cash injection to progress first-in-class therapy for inflammation and fibrosis

August 17, 2022

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

July 27, 2022

Vaxxas patch worked for all Covid strains

July 20, 2022

Australia’s first national biotech incubator announces round one funding to support life science breakthroughs

July 19, 2022

CUREator, the national biotechnology incubator, backs 23 start ups

July 5, 2022

CSIRO and Australian incubator CUREator boost health security innovation

June 9, 2022

Amaroq Therapeutics hits early milestones and makes key appointments to Scientific Advisory Board

May 31, 2022

Vaxxas and University of Sydney complete study assessing needle-free HD-MAP technology for vaccine administration

May 18, 2022

Australian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials

May 12, 2022

ENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray

May 12, 2022

Glyscend Therapeutics Announces Completion of Phase 1 Clinical Trial of its Oral, Gut-restricted, Polymer Therapeutic, GLY-200, as a Potential Type 2 Diabetes Treatment

May 10, 2022

Opinion: Aduhelm – Providing hope to millions of Alzheimer’s Disease patients worldwide? – Katherine Jackman

May 6, 2022

Aravax appoints Dr Brett Haumann to Board of Directors

May 3, 2022

Australian collaboration and AU$10m investment fuels Ankere Therapeutics’ efforts to target inflammatory lung conditions

April 16, 2022

Parkinson’s patients benefit from revolutionary watch on the NHS to manage care at home

April 12, 2022

Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022

April 4, 2022

Boosting product confidence of a world-leading RNA therapeutics start-up

March 24, 2022

Vaxxas Licenses HexaPro Spike Glycoprotein from University of Texas at Austin for Use on its Needle-Free Vaccine Patches

March 16, 2022

First Participants Dosed in Phase 2a Study of Pan-Antiviral Nasal Spray

March 9, 2022

Medical Research Commercialisation Fund (MRCF) renamed Brandon BioCatalyst

March 4, 2022

Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy

February 23, 2022

ENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray

February 18, 2022

PolyActiva Announces Positive Phase IIa Trial Results in Low Dose Cohort for PA5108 Ocular Implant with Prezia™ Sustained Drug Delivery Technology

January 17, 2022

Clinical trial begins in the UK to investigate 3-in-1 high blood pressure pill

January 12, 2022

Opinion: It’s time to make our own supply of lifesaving drugs – Chris Nave

December 23, 2021

Opinion: Why Australia needs a national biomedical incubator – Simon Wilkins

November 30, 2021

Q-Sera enters exclusive agreement with Terumo Corporation for RAPClot™ rapid serum blood collection tube technology in Japan

November 27, 2021

Healthy Outlook: Where your super is invested

November 24, 2021

Silicon Valley pacemaker hopes to capture Aussie hearts with ASX float

November 19, 2021

Hard WA border a boon for life sciences sector

November 11, 2021

Life science researchers and entrepreneurs encouraged to seek investment from new $40m Australian biotech incubator

September 29, 2021

Glyscend Therapeutics Announces Initiation of Phase 1 Clinical Trial on the Heels of Preclinical Data Presented at EASD 2021 on the Metabolic Benefits of its Oral Polymer-based Duodenal Exclusion Therapy

September 28, 2021

First-in-Class, Broad-Spectrum Nasal Spray to Prevent COVID-19 and Other Common Respiratory Illnesses Set to Begin Phase 2 Trials

September 23, 2021

Drug repurposing is no panacea in race to treat COVID-19

September 16, 2021

Allay Therapeutics Completes Oversubscribed $60M Financing to Advance Ultra-Sustained Pain Platform

September 15, 2021

Hope offered to Australians suffering from a rare incurable fibrotic autoimmune disease, as clinical trials on new treatment commence

September 7, 2021

Azura Ophthalmics Appoints Biopharma Industry Veteran Steven Altschuler, M.D. as Chair of the Board

August 23, 2021

‘New dawn’ for biotech with taxpayer-funded incubator

August 23, 2021

Australia’s first national biotech incubator established with $40m MRFF investment

August 19, 2021

Global Kinetics Enters Remote Monitoring Business and Appoints New U.S. Commercial Leadership

August 13, 2021

Federal Government backs MRCF-led program to support women into top STEM leadership positions with $1m funding

August 3, 2021

Adelaide Type 2 Diabetes researchers zero in on an ‘operation in a pill’

August 3, 2021

Glyscend Therapeutics commences South Australia Phase I clinical trial to progress new type 2 diabetes treatment

July 14, 2021

Promising Australian COVID-19 preventative nasal spray commences Sydney Phase I clinical trial, seeks participants

July 12, 2021

George Medicines appoints Dr Charmaine Gittleson as Non-Executive Director

July 8, 2021

Brandon Capital leads $14m investment to develop new cancer drug

July 8, 2021

$14m invested in world-leading RNA therapy: University of Otago spinout targeting new cancer treatments

July 1, 2021

George Medicines initiates two Phase III trials of triple combination candidate to treat hypertension

June 28, 2021

Brandon Capital, Uniseed back cancer biotech start-up in $10m funding

June 28, 2021

$10m invested into start-up developing new treatments targeting the use of CAR-T cell therapies against solid tumours

June 21, 2021

Forrest backs nasal spray play in fight against COVID-19

June 16, 2021

Australian spinout eyes the clinic with a prophylactic nasal spray for Covid-19

June 15, 2021

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Fund Raise

June 3, 2021

George Medicines appoints Stefan König as Chief Executive Officer

June 3, 2021

Preclinical studies from Vaxxas and Collaborators Reveal Potential of Vaxxas’ Novel High-Density Microarray Patch (HD-MAP) to Effectively Deliver SARS-CoV-2 Spike Vaccine

May 26, 2021

Researcher rewards needed to fuel biotech boom

May 23, 2021

‘No amount could be enough’: Calls for Canberra to back biotech, as medtech firms await funding

May 14, 2021

Adelaide’s BioMed City is attracting strong clinical trial interest as its critical mass continues to grow

May 13, 2021

Allay Therapeutics Launches with First Clinical Data to Demonstrate Weeks of Pain Relief with Ultra-Sustained Non-Opioid Platform

May 12, 2021

Tax breaks tipped to trigger innovation boom

May 12, 2021

First REDI Fellowships Awarded to Boost Medical Research Commercialisation Capabilities

May 11, 2021

Researchers cannot be expected to commercialise their innovations alone says leading IP lawyer and new MRCF Board member

May 11, 2021

‘IP Box’ regime would keep vaccines here

May 3, 2021

FDA fast-tracks Australian breast cancer technology

May 3, 2021

FDA grants Australian breast cancer innovation ‘Breakthrough Device Designation’ status

April 22, 2021

Strong quarter for Osprey with continued growth in units and revenue

April 15, 2021

World’s First Leadless Left Bundle Branch Area Pacing Implant Utilizing EBR Systems’ WiSE CRT System

April 9, 2021

VC Land Podcast: Shining a light on biotech with Brandon Capital

March 16, 2021

Tech leaders call for national plan, software R&D and IP tax cuts

March 8, 2021

Azura heads for final studies for world-first dry eye treatment

March 8, 2021

Women in science: Tackling gender diversity in top jobs

March 4, 2021

Remove red tape to speed new drugs to market, says research CEO

March 4, 2021

Promising new potential treatment for leading cause of Dry Eye Disease a step closer as Azura Ophthalmics announces positive results in Phase 2 Program

March 2, 2021

Industry-led leadership programme launched to support women into more top science and innovation roles

January 22, 2021

OncoRes Medical receives $150,000 funding boost from Western Australian Government

December 21, 2020

With health policy top of the political agenda, now’s the time to supercharge Australia’s biotech sector says new MRCF Board member

December 21, 2020

Erica Kneipp tapped for $700m biotech fund

December 18, 2020

Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals

November 22, 2020

Nasal spray which could fight Covid and other respiratory infections gets funding

November 17, 2020

New investments for drug research

November 16, 2020

Myricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer

November 6, 2020

PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period

November 1, 2020

Aravax appoints Financial Executive Thomas Ulmer to Board of Directors

October 29, 2020

OncoRes Medical wins IGNITE Madness 2020

October 26, 2020

Eyeing pandemic’s silver lining for drug trials

October 23, 2020

Azura Ophthalmics raises AUD$28m for registration studies for treatment of leading cause of dry eye disease

October 5, 2020

Vaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response

September 28, 2020

Preventative nasal spray shown to reduce viral replication by up to 96% in COVID-19 challenge study

September 28, 2020

Nasal spray cuts COVID-19 growth, study shows

September 3, 2020

Biomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions

July 30, 2020

GE Healthcare to Distribute Osprey Medical’s Technology to Address Angiography Based Acute Kidney Injury (AKI)

July 20, 2020

OncoRes Medical awarded prestigious research funding

June 12, 2020

Innovative type two diabetes treatment scores $29m

June 12, 2020

$29M investment to develop new treatment for type 2 diabetes

May 29, 2020

Vaxxas announces that MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

May 28, 2020

Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)

May 25, 2020

Nation faces ‘generational loss’ of biotechs warning

May 8, 2020

Urgent COVID-19 response package needed to support and protect $170b life sciences sector

March 24, 2020

Bill Ferris, pioneer venture capitalist, appointed Chair of the MRCF

March 18, 2020

Vaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin

March 18, 2020

Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination

March 10, 2020

Multi-million-dollar mission to tackle major global health challenges

December 16, 2019

MRCF establishes life science incubator to boost NZ startup successes

October 23, 2019

QUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats

September 26, 2019

$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease

September 10, 2019

FDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System

August 28, 2019

Perth tech joint-winner in global finals for international start-up competition

August 27, 2019

EBR Systems Closes $30M in New Funding, John McCutcheon Joins Company as President and CEO

August 20, 2019

Q-Sera’s innovative blood clotting technology granted patent in US

August 1, 2019

QUE Oncology launches Phase II trials in New Zealand

July 29, 2019

QUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors

July 23, 2019

PolyActiva completes recruitment in key Phase I glaucoma implant safety study.

May 22, 2019

Morphoseq™ at ‘Sequencing, Finishing and Analysis in the Future’ meeting, USA

May 16, 2019

Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology

May 1, 2019

Brandon Capital Partners launches new Medical Research Commercialisation Fund, seeks NZ institutional

April 2, 2019

QUE Oncology launches Phase II trials in the United States

March 15, 2019

MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

February 25, 2019

Aravax reveals positive Phase I trial results at world-leading allergy conference

January 31, 2019

Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis

December 3, 2018

Perth tech takes out Australian start-up competition to join international finals

November 21, 2018

The WILD Program launches within the Victorian STEM sector, with first intake of 20 women

October 2, 2018

QUE Oncology launches Phase II trials

August 31, 2018

PolyActiva commences first Phase I clinical trial with potential to improve lives of millions

August 14, 2018

Paragen Bio launches in northern Queensland with $6 million investment

June 4, 2018

MRCF announces largest investment to date by Biotechnology Translation Fund

February 28, 2018

MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia

February 19, 2018

Australian biotech company launched with AU$7m investment to develop therapies for treating obesity

February 13, 2018

Auspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections

December 13, 2017

New Zealand biomedical discovery set to revolutionise the global pain relief drug market

November 27, 2017

Q-Sera’s innovative blood clotting technology patent granted in China

November 11, 2017

Australian investors lead AU$60m raise to develop new technology

November 3, 2017

Osprey Medical and AKI highlighted at largest international cardiovascular conference TCT 2017

October 23, 2017

Q-Sera’s ground-breaking blood clotting technology presented at leading scientific conference in South Africa

February 17, 2025

January 28, 2025

January 22, 2025

January 13, 2025

December 23, 2024

December 19, 2024

December 11, 2024

December 6, 2024

November 21, 2024

November 1, 2024

October 28, 2024

October 18, 2024

October 14, 2024

September 16, 2024

September 11, 2024

September 6, 2024

September 5, 2024

August 27, 2024

July 16, 2024

July 8, 2024

May 22, 2024

May 21, 2024

May 13, 2024

May 7, 2024

April 29, 2024

April 18, 2024

April 2, 2024

March 1, 2024

February 15, 2024

January 23, 2024

December 6, 2023

November 27, 2023

November 26, 2023

November 16, 2023

November 15, 2023

November 2, 2023

October 19, 2023

October 9, 2023

September 27, 2023

September 27, 2023

September 11, 2023

September 5, 2023

August 23, 2023

August 15, 2023

August 3, 2023

July 18, 2023

June 6, 2023

June 6, 2023

June 2, 2023

May 24, 2023

May 22, 2023

May 3, 2023

March 21, 2023

March 10, 2023

March 9, 2023

February 14, 2023

February 10, 2023

February 6, 2023

January 19, 2023

January 10, 2023

December 20, 2022

December 20, 2022

December 6, 2022

December 6, 2022

November 22, 2022

November 17, 2022

November 11, 2022

November 9, 2022

November 9, 2022

November 9, 2022

November 4, 2022

November 4, 2022

November 2, 2022

October 20, 2022

October 12, 2022

September 28, 2022

September 28, 2022

September 21, 2022

September 21, 2022